Labcorp plans laboratory expansion in Japan through BML collaboration

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 28, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.

Walgreens and Labcorp offer at-home COVID-19 PCR test collection kits at no cost nationwide

Collaboration expands access to convenient testing at no cost for eligible individuals DEERFIELD, Ill., and BURLINGTON, N.C., March 7, 2022 – Walgreens and Labcorp, a leading global life sciences company, today announced the nationwide [i] availability of Pixel by Labcorp® [ii] COVID-19 at-home collection kit, a PCR test available through Labcorp OnDemand™, at no cost to individuals who meet clinical guidelines*.

Labcorp earns 100% on Human Rights Campaign Foundation’s annual scorecard on LGBTQ+ Workplace Equality

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 27, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received a perfect score of 100% on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

Labcorp and Community Clinical Oncology Research Network Collaborate to Assess Social and Economic Impacts of Disparities in Cancer Care

BURLINGTON, N.C. & EDISON, N.J. --(BUSINESS WIRE)--Aug. 19, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and Community Clinical Oncology Research Network, LLC (CCORN), a leading research organization, today announced their collaboration to better understand the impact of disparities in precision medicine for people with cancer. Information gathered from a patient registry and biobank will be used to help design future cancer clinical trials in diverse populations.

LabCorp Announces 2020 First Quarter Results

Q1 revenue of $2.82 billion , up 1% over $2.79 billion last year Q1 diluted EPS of ( $3.27 ), which include goodwill and other asset impairments of $4.43 per share Q1 adjusted EPS of $2.37 , which were negatively impacted by an estimated $0.55 per share from the COVID-19 pandemic Q1 free cash flow

LabCorp COVID-19 Antibody Tests Available Nationwide With No Upfront Out-of-Pocket Costs

Locations include nearly 2,000 LabCorp patient service centers including more than 100 LabCorp at Walgreens locations, and thousands of physicians’ offices BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 27, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in

LabCorp Broadens Availability of COVID-19 Serological Antibody Tests to Hospitals, Healthcare Organizations and Through Its Patient Service Centers

Tests Assist in Confirming the Presence of Antibodies to the Virus that Causes COVID-19 BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 22, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced it will expand serological

LabCorp COVID-19 At-Home Test Kit Receives FDA Emergency Use Authorization

Initial Distribution Prioritized for Frontline Healthcare Workers and First Responders BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 21, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it has received an Emergency

LabCorp and Ciox Health Enter Collaboration to Create Comprehensive Patient Data Registry

Groundbreaking Registry Aims to Help Researchers Accelerate COVID-19 Diagnosis, Treatment and Prevention Strategies BURLINGTON, N.C. & ALPHARETTA, Ga. --(BUSINESS WIRE)--Apr. 9, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and

Pacific Biosciences Powers SARS-CoV-2 Research at Commercial, Academic and Government Labs

LabCorp, UC San Diego and the National Institute of Allergy and Infectious Diseases are among the organizations utilizing PacBio’s highly accurate long-read sequencing technology to study SARS-CoV-2 and the related immune response to COVID-19   MENLO PARK, Calif., April 8, 2020 — Pacific